Comparison of the Efficacy and Safety of Zotarolimus-, Sirolimus-, and Paclitaxel-Eluting Stents in Patients With ST-Elevation Myocardial Infarction

Cheol Whan Lee, Duk Woo Park, Seung Hwan Lee, Young Hak Kim, Myeongki Hong, Jae Joong Kim, Seong Wook Park, Sung Cheol Yun, In Whan Seong, Jae Hwan Lee, Nae Hee Lee, Yoon Haeng Cho, Sang Sig Cheong, Do Sun Lim, Joo Young Yang, Sang Gon Lee, Kee Sik Kim, Junghan Yoon, Myung Ho Jeong, Ki Bae SeungTaeg Jong Hong, Seung Jung Park

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Drug-eluting stents (DESs) are increasingly used for treatment of acute ST-segment elevation myocardial infarction (STEMI), but there are few comparisons of outcomes of various types of DES. We compared the efficacy and safety of zotarolimus-eluting stents (ZESs), sirolimus-eluting stents (SESs), and paclitaxel-eluting stents (PESs) in primary intervention for STEMI. This multicenter, prospectively randomized ZEST-AMI trial included 328 patients at 12 medical centers who were randomly assigned to ZES (n = 108), SES (n = 110), or PES (n = 110) deployment. The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months. Secondary end points included the individual components of the primary end point, late loss, angiographic restenosis, and stent thrombosis. Baseline clinical and angiographic characteristics were well matched. In-segment late loss (0.28 ± 0.42 vs 0.46 ± 0.48 vs 0.47 ± 0.50 mm, respectively, p = 0.029) and restenosis rate (2.7% vs 15.9% vs 12.3%, respectively, p = 0.027) at 8 months were lowest in the SES group compared to the ZES and PES groups. At 12 months, cumulative incidence rates of primary end points in the ZES, SES, and PES groups were 11.3%, 8.2%, and 8.2%, respectively (p = 0.834). There were 2 acute (in the SES group) and 5 subacute (2 in the SES group and 3 in the PES group) stent thromboses. Incidence of death, recurrent MI, or ischemia-driven target vessel revascularization did not differ among the 3 groups. In conclusion, despite the difference in restenosis rate, the efficacy and safety of the 3 different DESs showed similar, acceptable results in the treatment of STEMI.

Original languageEnglish
Pages (from-to)1370-1376
Number of pages7
JournalAmerican Journal of Cardiology
Volume104
Issue number10
DOIs
Publication statusPublished - 2009 Nov 15

Fingerprint

Sirolimus
Paclitaxel
Stents
Safety
Drug-Eluting Stents
ST Elevation Myocardial Infarction
zotarolimus
Thrombosis
Ischemia
Incidence

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Lee, Cheol Whan ; Park, Duk Woo ; Lee, Seung Hwan ; Kim, Young Hak ; Hong, Myeongki ; Kim, Jae Joong ; Park, Seong Wook ; Yun, Sung Cheol ; Seong, In Whan ; Lee, Jae Hwan ; Lee, Nae Hee ; Cho, Yoon Haeng ; Cheong, Sang Sig ; Lim, Do Sun ; Yang, Joo Young ; Lee, Sang Gon ; Kim, Kee Sik ; Yoon, Junghan ; Jeong, Myung Ho ; Seung, Ki Bae ; Hong, Taeg Jong ; Park, Seung Jung. / Comparison of the Efficacy and Safety of Zotarolimus-, Sirolimus-, and Paclitaxel-Eluting Stents in Patients With ST-Elevation Myocardial Infarction. In: American Journal of Cardiology. 2009 ; Vol. 104, No. 10. pp. 1370-1376.
@article{953f0b70b0774486bf17279a66371d33,
title = "Comparison of the Efficacy and Safety of Zotarolimus-, Sirolimus-, and Paclitaxel-Eluting Stents in Patients With ST-Elevation Myocardial Infarction",
abstract = "Drug-eluting stents (DESs) are increasingly used for treatment of acute ST-segment elevation myocardial infarction (STEMI), but there are few comparisons of outcomes of various types of DES. We compared the efficacy and safety of zotarolimus-eluting stents (ZESs), sirolimus-eluting stents (SESs), and paclitaxel-eluting stents (PESs) in primary intervention for STEMI. This multicenter, prospectively randomized ZEST-AMI trial included 328 patients at 12 medical centers who were randomly assigned to ZES (n = 108), SES (n = 110), or PES (n = 110) deployment. The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months. Secondary end points included the individual components of the primary end point, late loss, angiographic restenosis, and stent thrombosis. Baseline clinical and angiographic characteristics were well matched. In-segment late loss (0.28 ± 0.42 vs 0.46 ± 0.48 vs 0.47 ± 0.50 mm, respectively, p = 0.029) and restenosis rate (2.7{\%} vs 15.9{\%} vs 12.3{\%}, respectively, p = 0.027) at 8 months were lowest in the SES group compared to the ZES and PES groups. At 12 months, cumulative incidence rates of primary end points in the ZES, SES, and PES groups were 11.3{\%}, 8.2{\%}, and 8.2{\%}, respectively (p = 0.834). There were 2 acute (in the SES group) and 5 subacute (2 in the SES group and 3 in the PES group) stent thromboses. Incidence of death, recurrent MI, or ischemia-driven target vessel revascularization did not differ among the 3 groups. In conclusion, despite the difference in restenosis rate, the efficacy and safety of the 3 different DESs showed similar, acceptable results in the treatment of STEMI.",
author = "Lee, {Cheol Whan} and Park, {Duk Woo} and Lee, {Seung Hwan} and Kim, {Young Hak} and Myeongki Hong and Kim, {Jae Joong} and Park, {Seong Wook} and Yun, {Sung Cheol} and Seong, {In Whan} and Lee, {Jae Hwan} and Lee, {Nae Hee} and Cho, {Yoon Haeng} and Cheong, {Sang Sig} and Lim, {Do Sun} and Yang, {Joo Young} and Lee, {Sang Gon} and Kim, {Kee Sik} and Junghan Yoon and Jeong, {Myung Ho} and Seung, {Ki Bae} and Hong, {Taeg Jong} and Park, {Seung Jung}",
year = "2009",
month = "11",
day = "15",
doi = "10.1016/j.amjcard.2009.06.059",
language = "English",
volume = "104",
pages = "1370--1376",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "10",

}

Lee, CW, Park, DW, Lee, SH, Kim, YH, Hong, M, Kim, JJ, Park, SW, Yun, SC, Seong, IW, Lee, JH, Lee, NH, Cho, YH, Cheong, SS, Lim, DS, Yang, JY, Lee, SG, Kim, KS, Yoon, J, Jeong, MH, Seung, KB, Hong, TJ & Park, SJ 2009, 'Comparison of the Efficacy and Safety of Zotarolimus-, Sirolimus-, and Paclitaxel-Eluting Stents in Patients With ST-Elevation Myocardial Infarction', American Journal of Cardiology, vol. 104, no. 10, pp. 1370-1376. https://doi.org/10.1016/j.amjcard.2009.06.059

Comparison of the Efficacy and Safety of Zotarolimus-, Sirolimus-, and Paclitaxel-Eluting Stents in Patients With ST-Elevation Myocardial Infarction. / Lee, Cheol Whan; Park, Duk Woo; Lee, Seung Hwan; Kim, Young Hak; Hong, Myeongki; Kim, Jae Joong; Park, Seong Wook; Yun, Sung Cheol; Seong, In Whan; Lee, Jae Hwan; Lee, Nae Hee; Cho, Yoon Haeng; Cheong, Sang Sig; Lim, Do Sun; Yang, Joo Young; Lee, Sang Gon; Kim, Kee Sik; Yoon, Junghan; Jeong, Myung Ho; Seung, Ki Bae; Hong, Taeg Jong; Park, Seung Jung.

In: American Journal of Cardiology, Vol. 104, No. 10, 15.11.2009, p. 1370-1376.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of the Efficacy and Safety of Zotarolimus-, Sirolimus-, and Paclitaxel-Eluting Stents in Patients With ST-Elevation Myocardial Infarction

AU - Lee, Cheol Whan

AU - Park, Duk Woo

AU - Lee, Seung Hwan

AU - Kim, Young Hak

AU - Hong, Myeongki

AU - Kim, Jae Joong

AU - Park, Seong Wook

AU - Yun, Sung Cheol

AU - Seong, In Whan

AU - Lee, Jae Hwan

AU - Lee, Nae Hee

AU - Cho, Yoon Haeng

AU - Cheong, Sang Sig

AU - Lim, Do Sun

AU - Yang, Joo Young

AU - Lee, Sang Gon

AU - Kim, Kee Sik

AU - Yoon, Junghan

AU - Jeong, Myung Ho

AU - Seung, Ki Bae

AU - Hong, Taeg Jong

AU - Park, Seung Jung

PY - 2009/11/15

Y1 - 2009/11/15

N2 - Drug-eluting stents (DESs) are increasingly used for treatment of acute ST-segment elevation myocardial infarction (STEMI), but there are few comparisons of outcomes of various types of DES. We compared the efficacy and safety of zotarolimus-eluting stents (ZESs), sirolimus-eluting stents (SESs), and paclitaxel-eluting stents (PESs) in primary intervention for STEMI. This multicenter, prospectively randomized ZEST-AMI trial included 328 patients at 12 medical centers who were randomly assigned to ZES (n = 108), SES (n = 110), or PES (n = 110) deployment. The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months. Secondary end points included the individual components of the primary end point, late loss, angiographic restenosis, and stent thrombosis. Baseline clinical and angiographic characteristics were well matched. In-segment late loss (0.28 ± 0.42 vs 0.46 ± 0.48 vs 0.47 ± 0.50 mm, respectively, p = 0.029) and restenosis rate (2.7% vs 15.9% vs 12.3%, respectively, p = 0.027) at 8 months were lowest in the SES group compared to the ZES and PES groups. At 12 months, cumulative incidence rates of primary end points in the ZES, SES, and PES groups were 11.3%, 8.2%, and 8.2%, respectively (p = 0.834). There were 2 acute (in the SES group) and 5 subacute (2 in the SES group and 3 in the PES group) stent thromboses. Incidence of death, recurrent MI, or ischemia-driven target vessel revascularization did not differ among the 3 groups. In conclusion, despite the difference in restenosis rate, the efficacy and safety of the 3 different DESs showed similar, acceptable results in the treatment of STEMI.

AB - Drug-eluting stents (DESs) are increasingly used for treatment of acute ST-segment elevation myocardial infarction (STEMI), but there are few comparisons of outcomes of various types of DES. We compared the efficacy and safety of zotarolimus-eluting stents (ZESs), sirolimus-eluting stents (SESs), and paclitaxel-eluting stents (PESs) in primary intervention for STEMI. This multicenter, prospectively randomized ZEST-AMI trial included 328 patients at 12 medical centers who were randomly assigned to ZES (n = 108), SES (n = 110), or PES (n = 110) deployment. The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months. Secondary end points included the individual components of the primary end point, late loss, angiographic restenosis, and stent thrombosis. Baseline clinical and angiographic characteristics were well matched. In-segment late loss (0.28 ± 0.42 vs 0.46 ± 0.48 vs 0.47 ± 0.50 mm, respectively, p = 0.029) and restenosis rate (2.7% vs 15.9% vs 12.3%, respectively, p = 0.027) at 8 months were lowest in the SES group compared to the ZES and PES groups. At 12 months, cumulative incidence rates of primary end points in the ZES, SES, and PES groups were 11.3%, 8.2%, and 8.2%, respectively (p = 0.834). There were 2 acute (in the SES group) and 5 subacute (2 in the SES group and 3 in the PES group) stent thromboses. Incidence of death, recurrent MI, or ischemia-driven target vessel revascularization did not differ among the 3 groups. In conclusion, despite the difference in restenosis rate, the efficacy and safety of the 3 different DESs showed similar, acceptable results in the treatment of STEMI.

UR - http://www.scopus.com/inward/record.url?scp=72049099355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72049099355&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2009.06.059

DO - 10.1016/j.amjcard.2009.06.059

M3 - Article

C2 - 19892052

AN - SCOPUS:72049099355

VL - 104

SP - 1370

EP - 1376

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 10

ER -